Protective effect of inhaled glucocorticosteroid and long-acting beta2-agonist combination on COPD model Source: Virtual Congress 2021 – Developments in biomarkers and treatment strategies for chronic lung diseases Year: 2021
Protective effect of inhaled anticholinergic drugs in the methacholine test Source: Eur Respir J 2007; 30: Suppl. 51, 619s Year: 2007
Efficacy of nebulized arformoterol, a long-acting β2 -adrenergic bronchodilator, in patients with COPD Source: Eur Respir J 2006; 28: Suppl. 50, 215s Year: 2006
Concomitant use of low-dose inhaled corticosteroids and a long-acting bronchodilatator visavi doubling the dose of inhaled corticosterod in asthma patients Source: Eur Respir J 2001; 18: Suppl. 33, 98s Year: 2001
Anti-inflammatory effect and clinical efficacy of concomitant treatments to steroid inhaler in bronchial asthma: montelukast versus salmeterol Source: Eur Respir J 2006; 28: Suppl. 50, 315s Year: 2006
Short-acting bronchodilator and oral steroid use in asthma patients prescribed either concurrent beclometasone and salmeterol or combined salmeterol/fluticasone Source: Eur Respir J 2004; 24: Suppl. 48, 309s Year: 2004
Cardioprotective effects of inhaled corticosteroid-containing combination therapy in COPD Source: Eur Respir J, 53 (2) 1802420; 10.1183/13993003.02420-2018 Year: 2019
Side effects of inhaled budesonide through different types of inhalers Source: International Congress 2019 – COPD treatment: clinical trials, cohorts and inhaler device studies Year: 2019
COPD: Comparison of bronchodilator responsiveness with glycopyrronium and salbutamol Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019
The effects of nebulised bronchodilators and corticosteroids treatment compared with inhaled drug therapy for moderate COPD patients Source: Eur Respir J 2004; 24: Suppl. 48, 290s Year: 2004
RPL554, an inhaled PDE3/4 inhibitor, causes comparable bronchodilation to high dose nebulised salbutamol in asthmatics with fewer systemic effects Source: International Congress 2016 – Novel mechanisms and treatment modalities in asthma Year: 2016
Inhaled corticosteroid combined with long-acting bronchodilator versus long-acting bronchodilator alone for older patients with COPD Source: International Congress 2015 – Advances in pneumonia management, COPD therapy and lung nodule evaluation Year: 2015
Cardiopulmonary effects of inhaled ipratropium bromide and its combination with fenoterol in patients with bronchial asthma Source: Eur Respir J 2002; 20: Suppl. 38, 58s Year: 2002
Low systemic exposure of NVA237, an inhaled once-daily anticholinergic bronchodilator, in healthy humans Source: Eur Respir J 2006; 28: Suppl. 50, 661s Year: 2006
Bronchoprotective and anti-inflammatory effect of beclometasone dipropionate plus formoterol HFA fixed combination in asthmatic patients Source: Annual Congress 2009 - Aspects of uncontrolled asthma Year: 2009
The effects of a crossover treatment with inhaled corticosteroids and N-acetylcysteine on lung function parameters in COPD-patients Source: Eur Respir J 2004; 24: Suppl. 48, 342s Year: 2004
Systemic effects and pharmacokinetics of a new CFC-free metered dose inhaler of beclomethasone dipropionate following multiple dosing in asthmatic patients Source: Eur Respir J 2005; 26: Suppl. 49, 180s Year: 2005
Effect of long-acting ß-agonist on bronchodilator response in children with asthma Source: Eur Respir J, 56 (3) 1902010; 10.1183/13993003.02010-2019 Year: 2020
Safety of formoterol reliever therapy compared with terbutaline in asthmatic children taking anti-inflammatory therapy Source: Eur Respir J 2002; 20: Suppl. 38, 431s Year: 2002
Impact of the combination therapy: inhaled corticosteroid and long-acting beta agonists in the prescription pattern of inhaled corticosteroids Source: Annual Congress 2007 - Respiratory issues in primary care Year: 2007